Rescue of fragile X syndrome phenotypes in Fmr1 KO mice by the small-molecule PAK inhibitor FRAX486

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 14, 2013, Pages 5671-5676

  Dolan, Bridget M ^a   Duron, Sergio G ^b   Campbell, David A ^b   Vollrath, Benedikt ^b   Shankaranarayana Rao, B S ^c   Ko, Hui Yeon ^d   Lin, Gregory G ^a   Govindarajan, Arvind ^a   Choi, Se Young ^d   Tonegawa, Susumu ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b Afraxis   (United States)

^c NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

^d Seoul National University   (South Korea)

Author keywords

Drug discovery; Neurodevelopmental disorder

Indexed keywords

FRAGILE X MENTAL RETARDATION PROTEIN; FRAX 486; P21 ACTIVATED KINASE; UNCLASSIFIED DRUG;

ACTIN FILAMENT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTISM; BLOOD BRAIN BARRIER; BLOOD SAMPLING; CONTROLLED STUDY; DENDRITIC SPINE; DOSE RESPONSE; DRUG BLOOD LEVEL; FRAGILE X SYNDROME; HYPERACTIVITY; MALE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESPIRATORY ARREST; SEIZURE; SINGLE DRUG DOSE; SYMPTOM;

ACTIN CYTOSKELETON; ANIMALS; DENDRITIC SPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DISCOVERY; EPILEPSY, REFLEX; FRAGILE X MENTAL RETARDATION PROTEIN; FRAGILE X SYNDROME; MALE; MICE; MICE, KNOCKOUT; MOLECULAR STRUCTURE; P21-ACTIVATED KINASES; PHENOTYPE; PROTEIN KINASE INHIBITORS; PYRIDONES; PYRIMIDINES; ROTAROD PERFORMANCE TEST; STRUCTURE-ACTIVITY RELATIONSHIP;

MUS;

EID: 84875844949     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1219383110     Document Type: Article

References (50)

1. Boyle CA, et al. (2011) Trends in the prevalence of developmental disabilities in US children, 1997-2008. Pediatrics 127(6):1034-1042.
2. McPheeters ML, et al. (2011) A systematic review of medical treatments for children with autism spectrum disorders. Pediatrics 127(5):e1312-e1321.
3. Hagerman RJ, et al. (2009) Advances in the treatment of fragile X syndrome. Pediatrics 123(1):378-390.
4. Abrahams BS, Geschwind DH (2008) Advances in autism genetics: On the threshold of a new neurobiology. Nat Rev Genet 9(5):341-355.
5. Verkerk AJ, et al. (1991) Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell 65(5):905-914.
6. The Dutch-Belgian Fragile X Consortium (1994) Fmr1 knockout mice: A model to study fragile X mental retardation. Cell 78(1):23-33.
7. Spencer CM, et al. (2011) Modifying behavioral phenotypes in Fmr1KO mice: Genetic background differences reveal autistic-like responses. Autism Res 4(1):40-56.
8. Hayashi ML, et al. (2007) Inhibition of p21-activated kinase rescues symptoms of fragile X syndrome in mice. Proc Natl Acad Sci USA 104(27):11489-11494.
9. Lewis MH, Tanimura Y, Lee LW, Bodfish JW (2007) Animal models of restricted repetitive behavior in autism. Behav Brain Res 176(1):66-74.
10. Chen L, Toth M (2001) Fragile X mice develop sensory hyperreactivity to auditory stimuli. Neuroscience 103(4):1043-1050.
11. Yan QJ, Asafo-Adjei PK, Arnold HM, Brown RE, Bauchwitz RP (2004) A phenotypic and molecular characterization of the fmr1-tm1Cgr fragile X mouse. Genes Brain Behav 3(6):337-359.
12. Yan QJ, Rammal M, Tranfaglia M, Bauchwitz RP (2005) Suppression of two major fragile X syndrome mouse model phenotypes by the mGluR5 antagonist MPEP. Neuropharmacology 49(7):1053-1066.
13. Dölen G, et al. (2007) Correction of fragile X syndrome in mice. Neuron 56(6):955-962.
14. Bhakar AL, Dölen G, Bear MF (2012) The pathophysiology of fragile X (and what it teaches us about synapses). Annu Rev Neurosci 35:417-443.
15. Michalon A, et al. (2012) Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice. Neuron 74(1):49-56.
16. Rudelli RD, et al. (1985) Adult fragile X syndrome. Clinico- neuropathologic findings. Acta Neuropathol 67(3-4):289-295.
17. Hinton VJ, Brown WT, Wisniewski K, Rudelli RD (1991) Analysis of neocortex in three males with the fragile X syndrome. Am J Med Genet 41(3):289-294.
18. Irwin SA, et al. (2001) Abnormal dendritic spine characteristics in the temporal and visual cortices of patients with fragile-X syndrome: A quantitative examination. Am J Med Genet 98(2):161-167.
19. Comery TA, et al. (1997) Abnormal dendritic spines in fragile X knockout mice: maturation and pruning deficits. Proc Natl Acad Sci USA 94(10):5401-5404.
20. Irwin SA, et al. (2002) Dendritic spine and dendritic field characteristics of layer V pyramidal neurons in the visual cortex of fragile-X knockout mice. Am J Med Genet 111(2):140-146.
21. Fukazawa Y, et al. (2003) Hippocampal LTP is accompanied by enhanced F-actin content within the dendritic spine that is essential for late LTP maintenance in vivo. Neuron 38(3):447-460.
22. Bramham CR (2008) Local protein synthesis, actin dynamics, and LTP consolidation. Curr Opin Neurobiol 18(5):524-531.
23. Tada T, Sheng M (2006) Molecular mechanisms of dendritic spine morphogenesis. Curr Opin Neurobiol 16(1):95-101.
24. Manser E, Leung T, Salihuddin H, Zhao ZS, Lim L (1994) A brain serine/threonine protein kinase activated by Cdc42 and Rac1. Nature 367(6458):40-46.
25. Allen KM, et al. (1998) PAK3 mutation in nonsyndromic X-linked mental retardation. Nat Genet 20(1):25-30.
26. Zhao L, et al. (2006) Role of p21-activated kinase pathway defects in the cognitive deficits of Alzheimer disease. Nat Neurosci 9(2):234-242.
27. Schenck A, et al. (2003) CYFIP/Sra-1 controls neuronal connectivity in Drosophila and links the Rac1 GTPase pathway to the fragile X protein. Neuron 38(6):887-898.
28. Castets M, et al. (2005) FMRP interferes with the Rac1 pathway and controls actin cytoskeleton dynamics in murine fibroblasts. Hum Mol Genet 14(6):835-844.
29. Chen LY, et al. (2010) Physiological activation of synaptic Rac>PAK (p-21 activated kinase) signaling is defective in a mouse model of fragile X syndrome. J Neurosci 30(33):10977-10984.
30. Hayashi ML, et al. (2004) Altered cortical synaptic morphology and impaired memory consolidation in forebrain-specific dominant-negative PAK transgenic mice. Neuron 42(5):773-787.
31. Deacon SW, et al. (2008) An isoform-selective, small-molecule inhibitor targets the autoregulatory mechanism of p21-activated kinase. Chem Biol 15(4):322-331.
32. Boda B, et al. (2004) The mental retardation protein PAK3 contributes to synapse formation and plasticity in hippocampus. J Neurosci 24(48):10816-10825.
33. Asrar S, et al. (2009) Regulation of hippocampal long-term potentiation by p21- activated protein kinase 1 (PAK1). Neuropharmacology 56(1):73-80.
34. Huang W, et al. (2011) p21-Activated kinases 1 and 3 control brain size through coordinating neuronal complexity and synaptic properties. Mol Cell Biol 31(3):388-403.
35. Pardridge WM (2005) The blood-brain barrier: Bottleneck in brain drug development. NeuroRx 2(1):3-14.
36. Berry-Kravis E (2002) Epilepsy in fragile X syndrome. Dev Med Child Neurol 44(11): 724-728.
37. Hara H (2007) Autism and epilepsy: A retrospective follow-up study. Brain Dev 29(8): 486-490.
38. Qin M, Kang J, Smith CB (2005) A null mutation for Fmr1 in female mice: Effects on regional cerebral metabolic rate for glucose and relationship to behavior. Neuroscience 135(3):999-1009.
39. American Psychiatric Association (1994) Diagnostic Criteria from DSM-IV (American Psychiatric Publishing, Washington, DC).
40. Hutsler JJ, Zhang H (2010) Increased dendritic spine densities on cortical projection neurons in autism spectrum disorders. Brain Res 1309:83-94.
41. Musumeci SA, et al. (1999) Epilepsy and EEG findings in males with fragile X syndrome. Epilepsia 40(8):1092-1099.
42. Musumeci SA, et al. (2007) Audiogenic seizure susceptibility is reduced in fragile X knockout mice after introduction of FMR1 transgenes. Exp Neurol 203(1):233-240.
43. Simonoff E, et al. (2008) Psychiatric disorders in children with autism spectrum disorders: Prevalence, comorbidity, and associated factors in a population-derived sample. J Am Acad Child Adolesc Psychiatry 47(8):921-929.
44. Backes M, et al. (2000) Cognitive and behavioral profile of fragile X boys: Correlations to molecular data. Am J Med Genet 95(2):150-156.
45. Fryns JP (1984) The fragile X syndrome. A study of 83 families. Clin Genet 26(6): 497-528.
46. Lai CS, Franke TF, Gan WB (2012) Opposite effects of fear conditioning and extinction on dendritic spine remodelling. Nature 483(7387):87-91.
47. Li N, et al. (2011) Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol Psychiatry 69(8):754-761.
48. Errijgers V, et al. (2007) FVB.129P2-Pde6b(+) Tyr(c-ch)/Ant, a sighted variant of the FVB/N mouse strain suitable for behavioral analysis. Genes Brain Behav 6(6):552-557.
49. Ramon-Moliner E (1970) The Golgi-Cox Technique in Contemporary Research Methods in Neuroanatomy (Springer, New York).
50. Vyas A, Mitra R, Shankaranarayana Rao BS, Chattarji S (2002) Chronic stress induces contrasting patterns of dendritic remodeling in hippocampal and amygdaloid neurons. J Neurosci 22(15):6810-6818.